Scholarlink

Introduction <p>Abrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis.</p> Methods <p>This post hoc analysis assessed the onset and depth of response of abrocitinib 100 or 200&#xa0;mg in achieving the stringent outcome of ≥ 90% improvement from baseline in the Eczema Area and Severity Index score and Peak Pruritus Numerical Rating score of 0 to 1 (EASI-90 + PP-NRS0/1) in the JADE DARE (NCT04345367) and JADE COMPARE (NCT03720470) clinical trials, and previous dupilumab inadequate responders in the JADE EXTEND (NCT03422822) clinical trial.</p> Results <p>Higher proportions of patients achieved EASI-90 + PP-NRS0/1 with abrocitinib 200&#xa0;mg (5.8%) versus dupilumab (1.1%) as early as week 2 in JADE DARE. In JADE COMPARE, 27.1% of patients treated with abrocitinib 200&#xa0;mg achieved EASI-90 + PP-NRS0/1 compared with 20.2% with abrocitinib 100&#xa0;mg, 15.5% with dupilumab, and 5.4% with placebo at week 16. Similar proportions of patients achieved this endpoint irrespective of baseline itch. Patients whose disease did not respond to dupilumab were able to achieve EASI-90 + PP-NRS0/1 with abrocitinib 200 or 100&#xa0;mg in JADE EXTEND (16.7% and 18.5%, respectively).</p> Conclusion <p>These findings suggest that minimal disease activity can be attained in patients with moderate-to-severe atopic dermatitis treated with abrocitinib, regardless of prior dupilumab exposure.</p> Trial Registration <p>Clinicaltrials.gov identifiers: NCT04345367 (JADE DARE), NCT03720470 (JADE COMPARE), NCT03422822 (JADE EXTEND).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月27日

查看全文
  • Stephen Weidinger,
  • Kristian Reich,
  • Naiem Issa,
  • H. Chih-ho Hong,
  • Christopher G. Bunick,
  • Pinaki Biswas,
  • Gary Chan,
  • Erman Güler,
  • Melissa Watkins,
  • Justine Alderfer

摘要

Introduction

Abrocitinib, a Janus kinase inhibitor, is approved for patients with moderate-to-severe atopic dermatitis.

Methods

This post hoc analysis assessed the onset and depth of response of abrocitinib 100 or 200 mg in achieving the stringent outcome of ≥ 90% improvement from baseline in the Eczema Area and Severity Index score and Peak Pruritus Numerical Rating score of 0 to 1 (EASI-90 + PP-NRS0/1) in the JADE DARE (NCT04345367) and JADE COMPARE (NCT03720470) clinical trials, and previous dupilumab inadequate responders in the JADE EXTEND (NCT03422822) clinical trial.

Results

Higher proportions of patients achieved EASI-90 + PP-NRS0/1 with abrocitinib 200 mg (5.8%) versus dupilumab (1.1%) as early as week 2 in JADE DARE. In JADE COMPARE, 27.1% of patients treated with abrocitinib 200 mg achieved EASI-90 + PP-NRS0/1 compared with 20.2% with abrocitinib 100 mg, 15.5% with dupilumab, and 5.4% with placebo at week 16. Similar proportions of patients achieved this endpoint irrespective of baseline itch. Patients whose disease did not respond to dupilumab were able to achieve EASI-90 + PP-NRS0/1 with abrocitinib 200 or 100 mg in JADE EXTEND (16.7% and 18.5%, respectively).

Conclusion

These findings suggest that minimal disease activity can be attained in patients with moderate-to-severe atopic dermatitis treated with abrocitinib, regardless of prior dupilumab exposure.

Trial Registration

Clinicaltrials.gov identifiers: NCT04345367 (JADE DARE), NCT03720470 (JADE COMPARE), NCT03422822 (JADE EXTEND).